Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD47

CD47

Brief Information

Name:Cluster of differentiation 47
Target Synonym:MER6,CD47,Leukocyte surface antigen CD47,CD47 Molecule,Antigenic Surface Determinant Protein OA3,CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer),Antigen Identified By Monoclonal Antibody 1D8,Integrin Associated Protein,Rh-Related Antigen,CD47 Glycoprotein,IAP,Integrin-Associated Signal Transducer,Protein MER6,OA3,CD47 Antigen,Integrin-Associated Protein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:55
Lastest Research Phase:Phase 3 Clinical

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
CD47 Monoclonal Antibody Monospecific antibody Oncology/Cancer Advanced solid tumor,Advanced hematological tumor IND Global

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD7-C82F3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque CD47 Protein, Fc,Avitag™ (MALS verified)
CD7-C82F3-structure
CD7-C82F3-sds
MBS-K080 Human APC-labeled Human CD47-coupled Magnetic Beads
CD7-C82E3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque CD47 Protein, His,Avitag™
CD7-C82E3-structure
CD7-C82E3-sds
EP-160 Human CD47 : SIRP gamma [Biotinylated] Inhibitor Screening ELISA Kit
CD7-M82F5 Mouse Biotinylated Mouse CD47 Protein, Fc,Avitag™ (MALS verified)
CD7-M82F5-structure
CD7-M82F5-sds
MBS-K059 Human PE-labeled Human CD47-coupled Magnetic Beads
EP-152 Human CD47 [Biotinylated] : SIRP alphaV2 Inhibitor Screening ELISA Kit
EP-138 Human CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit
MBS-K023 Human Human CD47-coupled Magnetic Beads
CD7-H82A3 Human Biotinylated Human CD47 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
CD7-H82A3-structure
CD7-H82A3-sds
CD7-HF2H3 Human FITC-Labeled Human CD47 Protein, His Tag
CD7-HF2H3-structure
CD7-HF2H3-sds
CD7-M82E4 Mouse Biotinylated Mouse CD47 Protein, His,Avitag™
CD7-M82E4-structure
CD7-M82E4-sds
CD7-C52H5 Canine Canine CD47 Protein, His Tag
CD7-C52H5-structure
CD7-C52H5-sds
EP-102 Human CD47: SIRP alpha [Biotinylated] Inhibitor Screening ELISA Assay Pair
CD7-H522a Human Human CD47 Protein, His Tag, low endotoxin
CD7-H522a-structure
CD7-H522a-sds
CD7-H5251 Human Human CD47 Protein, Llama IgG2b Fc Tag, low endotoxin
CD7-H5251-structure
CD7-H5251-sds
CD7-M525a Mouse Mouse CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin
CD7-M525a-structure
CD7-M525a-sds
CD7-M522b Mouse Mouse CD47 Protein, His Tag (MALS verified)
CD7-M522b-structure
CD7-M522b-sds
CD7-C52H1 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD47 Protein, His Tag
CD7-C52H1-structure
CD7-C52H1-sds
CD7-HA2E9 Human Unconjugated Human CD47 Protein, His,Avitag™
CD7-HA2E9-structure
CD7-HA2E9-sds
CD7-H82E9 Human Biotinylated Human CD47 Protein, His,Avitag™
CD7-H82E9-structure
CD7-H82E9-sds
CD7-R5257 Rabbit Rabbit CD47 Protein, Fc Tag
CD7-R5257-structure
CD7-R5257-sds
CD7-R5256 Rat Rat CD47 Protein, Fc Tag
CD7-R5256-structure
CD7-R5256-sds
CD7-H52A5 Human Human CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin
CD7-H52A5-structure
CD7-H52A5-sds
CD7-C5252 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD47 Protein, Fc Tag
CD7-C5252-structure
CD7-C5252-sds
CD7-M5251 Mouse Mouse CD47 Protein, Fc Tag
CD7-M5251-structure
CD7-M5251-sds
CD7-H82F6 Human Biotinylated Human CD47 Protein, Fc,Avitag™
CD7-H82F6-structure
CD7-H82F6-sds
CD7-H5227 Human Human CD47 Protein, His Tag (MALS verified)
CD7-H5227-structure
CD7-H5227-sds
CD7-H5256 Human Human CD47 Protein, Fc Tag (MALS verified)
CD7-H5256-structure
CD7-H5256-sds
ACRO Quality

Part of Bioactivity data

CD7-H82E9-Cell-based assay
 CD47 FACS

FACS assay shows that Biotinylated Human CD47, His,Avitag (Cat. No. CD7-H82E9) can bind to ACHN cell expressing human SIRP-a. The concentration of CD47 used is 10 μg/mL (Routinely tested).

CD7-H82E9-Cell-based assay
 CD47 FACS

FACS analysis shows that the binding of Human CD47 to ACHN expressing SIRP-a was inhibited by increasing concentration of neutralizing SIRP-a antibody. The concentration of Human CD47 used is 20 μg/mL. IC50=9.334 μg/mL

CD7-C52H1-SPR
 CD47 SPR

Anti-CD47 Mab (Human IgG4) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Cynomolgus/Rhesus macaque CD47, His Tag (Cat. No. CD7-C52H1) with an affinity constant of 1.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD7-H5227-SPR
 CD47 SPR

Anti-Human CD47 MAb (Human IgG4) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human CD47, His Tag (Cat. No. CD7-H5227) with an affinity constant of 1.66 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CD47,MER6,IAP,OA3

Background

Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Letaplimab IBI-188 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Adenocarcinoma of Lung; Neoplasms; Myelodysplastic Syndromes; Osteosarcoma; Leukemia, Myeloid, Acute Details
LD-002 LD-002 Phase 1 Clinical Zhejiang Blue Shield Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin Details
AUR-105 AUR-105 Phase 1 Clinical Aurigene Solid tumours; Hodgkin Disease; Lymphoma, Non-Hodgkin Details
Magrolimab 5-F-9; Hu5F9-G4; ONO-7913 Phase 3 Clinical Stanford University Urinary Bladder Neoplasms; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Sezary Syndrome; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Osteosarcoma; Neuroblastoma; Brain Neoplasms; Multiple Myeloma; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Leukemia, Lymphoid; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid; Ovarian Neoplasms; Lymphoma, B-Cell Details
FP-002 (Fapon Biopharma) FP-002 Phase 1 Clinical Fapon Biotech Inc Solid tumours; Neoplasms Details
Lemzoparlimab TJC-4; ABBV-IMAB-TJC4; TJ-1133; TJ-011133 Phase 3 Clinical I-Mab Biopharma Co Ltd, Abbvie Inc Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma Details
Timdarpacept IMM01; IMM 01 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Hodgkin Disease; Multiple Myeloma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin Details
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Swiss Biopharma Med GmbH Pyoderma Gangrenosum; Pyoderma Details
SG12473 SG12473; SG-12473 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms Details
HX-009 HX-009 Phase 2 Clinical Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma Details
STI-6643 STI-6643 Phase 1 Clinical Sorrento Therapeutics Inc Solid tumours; Neoplasms Details
NI-1801 NI-1801 Phase 1 Clinical Light Chain Bioscience Ltd Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung Details
AUR-103 AUR-103 Phase 1 Clinical Aurigene Leukemia; Solid tumours; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute Details
IMM-2520 IMM-2520 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
D3L-001 D3L-001 Phase 1 Clinical D3 Bio (Wuxi) Co Ltd Solid tumours; Neoplasms Details
SHS-009 SHS-009; SH009; SH-009 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Neoplasms Details
BC-007 (Dragonboat Biopharmaceutical) BC-007 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
SG-1906 SG-1906; SG1906 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours; Neoplasms Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jmt-Bio Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Simridarlimab IBI-322; IBI322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Solid tumours; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell Details
Recombinant humanized monoclonal antibody MIL95(Mabworks/Connaught Biomedical Technology) MIL-95; CM-312 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd, Keymed Biosciences Co Ltd Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma Details
IMC-002(Immuneoncia) IMC-002; 3D-197; 3D197 Phase 1 Clinical Immuneoncia Therapeutics Inc Solid tumours; Hematologic Neoplasms; Neoplasms; Lymphoma; Neoplasm Metastasis Details
Kintuzumab(GenSci) Phase 1 Clinical Changchun GeneScience Pharmaceuticals Co Ltd Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma Details
CC-90002 INBRX-103; CC-90002 Phase 1 Clinical Inhibrx Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Maplirpacept TTI-622; PF-07901801 Phase 2 Clinical Trillium Therapeutics Inc Hematologic Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms; Carcinoma, Ovarian Epithelial; Multiple Myeloma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Myeloid, Acute Details
Urabrelimab SRF-231 Phase 1 Clinical Surface Oncology Inc Hematologic Neoplasms; Solid tumours Details
SG404 SG-404; SG404 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Neoplasms Details
DSP-107 DSP-107; KAHR-107 Phase 2 Clinical Kahr Medical Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
PF-07257876 Phase 1 Clinical Pfizer Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
IMM-2902 IMM-2902 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours; Stomach Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
AK-132 AK132; AK-132 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms Details
HMPL-A83 HMPL-A-83; HMPL-A83 Phase 1 Clinical Hutchison Medipharma Ltd Solid tumours; Hematologic Neoplasms; Neoplasms Details
SL-172154 SL-172154 Phase 1 Clinical Shattuck Labs Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute Details
IMM2505 IMM2505; IMM-2505 Phase 1 Clinical SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
SG-2501 SG-2501 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Lymphoma Details
IMM-0306 IMM-0306 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
6MW-3211 6MW3211; 6MW-3211 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma Details
HCB-101 HCB-101 Phase 1 Clinical HanchorBio Inc Solid tumours; Lymphoma, Non-Hodgkin Details
ISB-1442 ISB 1442; ISB-1442 Phase 2 Clinical Ichnos Sciences Sa Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
Ontorpacept TTI-621 Phase 2 Clinical The Hospital For Sick Children, University Health Network, Trillium Therapeutics Inc Multiple Myeloma; Mycosis Fungoides; Melanoma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Sarcoma; Breast Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Leiomyosarcoma; Neoplasms; Papillomavirus Infections; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Merkel Cell; Hematologic Neoplasms; Solid tumours; Lymphoma, B-Cell Details
BAT-7104 BAT-7104 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
ZL-1201 ZL-1201 Phase 1 Clinical Zai Lab (Shanghai) Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms Details
Ligufalimab AK-117 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Myelodysplastic Syndromes; Triple Negative Breast Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma Details
Zeripatamig NI-1701; TG-1801 Phase 1 Clinical Novimmune Sa Lymphoma, B-Cell Details
Anti-CD47 monoclonal antibody (Biocad) Phase 1 Clinical Biocad Neoplasms Details
PT-886 PT-886 Phase 1 Clinical Phanes Therapeutics Inc Stomach Neoplasms; Pancreatic Neoplasms Details
AO-176 AO-176; Ti-104; Ti-108; Ti-176 Phase 2 Clinical Arch Oncology Inc Solid tumours; Multiple Myeloma Details
Evorpacept ALX148; ALX-148 Phase 3 Clinical Alexo Therapeutics Urinary Bladder Neoplasms; Neoplasm Metastasis; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Plasmablastic Lymphoma; Solid tumours; Carcinoma, Transitional Cell; Composite Lymphoma; Neoplasms; Myelodysplastic Syndromes; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Head and Neck Neoplasms Details
PT-217 PT-217 Phase 1 Clinical Phanes Therapeutics Inc Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Prostatic Neoplasms; Carcinoma, Neuroendocrine Details
TQB-2928 TQB-2928 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute Details
LB-101 (Centessa Pharmaceuticals) LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody Phase 2 Clinical Centessa Pharmaceuticals Plc Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message